GlassScriptPhysician profile
Melissa M Kuzo
NPI 1124471669
$7,878.77
in general payments reported to CMS, 2019-2025
22 companies · $2,561 in 2025
The $2,561 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $138 · 2021: $53.38 · 2022: $546 · 2023: $2,882 · 2024: $1,272 · 2025: $2,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,076 · Travel and Lodging: $1,440 · Consulting Fee: $180 · Entertainment: $19.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,076.30 |
| Travel and Lodging | $1,440.48 |
| Consulting Fee | $179.66 |
| Entertainment | $19.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,099.64 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $1,145.56 | 2022-2025 | Miebo, Xiidra, Infuse |
| Lumenis Be INC | $1,109.95 | 2023-2025 | Optilight |
| Alcon Vision LLC | $802.04 | 2019-2025 | Precision7, Precision 1, Tryptyr |
| Oyster Point Pharma, INC. | $620.43 | 2022-2024 | Tyrvaya |
| Lkc Technologies, INC. | $307.03 | 2023-2025 | |
| Coopervision INC. | $306.74 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $276.31 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $227.31 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $215.40 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $199.23 | 2024-2025 | Xdemvy |
| Topcon Healthcare, INC. | $147.46 | 2023-2024 | |
| Johnson & Johnson Vision Care, INC. | $124.92 | 2019-2023 | Acuvue |
| Eyevance Pharmaceuticals LLC | $74.66 | 2021-2023 | Flarex |
| Genzyme Corporation | $60.35 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.14 | 2020-2022 | |
| Sight Sciences, INC. | $22.54 | 2023 | Tearcare System |
| Allergan, INC. | $20.81 | 2022 | |
| Quidel Corporation | $20.79 | 2022 | |
| Optos, INC. | $19.05 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Kuzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.